Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Melanoma 19Neuroblastoma 16Leukemia 15Prostatic Neoplasms 14Lymphoma 12Multiple Myeloma 10Breast Neoplasms 10Lymphoma, Non-Hodgkin 8Leukemia, Myeloid, Acute 8Leukemia, Lymphocytic, Chronic, B-Cell 8Glioblastoma 8Neoplasm Metastasis 6Myelodysplastic Syndromes 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Fallopian Tube Neoplasms 6Neoplasms 5Hodgkin Disease 5Carcinoma, Non-Small-Cell Lung 5Uveal Melanoma 4Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Kidney Neoplasms 4Glioma 4Carcinoma, Renal Cell 4Carcinoma, Ovarian Epithelial 4Breast Neoplasms, Male 4Ovarian Neoplasms 3Neoplasms, Plasma Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3

Interventions

Radiation Dose Hypofractionation 2Immune Checkpoint Inhibitors 2Granulocyte-Macrophage Colony-Stimulating Factor 2envafolimab 1N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Advanced Refractory Solid Tumors × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT07327411 2026-01-08

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

Second Affiliated Hospital of Soochow University

Phase 2 Not yet recruiting
40 enrolled
Other solid neoplasm

Advanced Refractory Solid Tumors

NCT04892498 2022-08-09

Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)

Second Affiliated Hospital of Soochow University

Phase 2 Unknown
66 enrolled
Other solid neoplasm

Advanced Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡